Spartalizumab
Showing 26 - 50 of 54
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin,
Completed
- Well-differentiated Non-functional NET of Thoracic Origin
- +3 more
-
Duarte, California
- +34 more
Mar 16, 2021
NSCLC (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in Worldwide (NZV930, PDR001,
Terminated
- Non-small Cell Lung Cancer (NSCLC)
- +6 more
- NZV930
- +2 more
-
Tampa, Florida
- +9 more
Nov 2, 2022
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Worldwide (Decitabine, PDR001, MBG453)
Active, not recruiting
- Leukemia
- +7 more
- Decitabine
- +3 more
-
Boston, Massachusetts
- +10 more
Jan 19, 2023
Metastatic Colorectal Cancer Trial in Sutton (PDR001, bevacizumab, mFOLFOX6)
Terminated
- Metastatic Colorectal Cancer
- PDR001
- +2 more
-
Sutton, Surrey, United KingdomNovartis Investigative Site
Oct 7, 2021
Metastatic Colorectal Cancer Trial in Boston (Dabrafenib, Trametinib, PDR001)
Recruiting
- Metastatic Colorectal Cancer
- Dabrafenib
- +2 more
-
Boston, Massachusetts
- +1 more
Jun 24, 2022
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Trial in
Completed
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- PDR001
- +5 more
-
Santa Monica, California
- +24 more
Mar 11, 2022
Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
Active, not recruiting
- Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
May 5, 2021
Gastrointestinal Stromal Tumors Trial in Seoul (PDR001, Imatinib)
Recruiting
- Gastrointestinal Stromal Tumors
- PDR001, Imatinib
-
Seoul, Korea, Republic ofAsan Medical Center
Jun 22, 2021
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
Terminated
- Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
- +2 more
- Ribociclib
- +2 more
-
Boston, Massachusetts
- +2 more
Mar 16, 2022
NSCLC (NSCLC) Trial in Tampa (PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg)
Completed
- Non-small Cell Lung Cancer (NSCLC)
- PBF-509_80 mg
- +8 more
-
Tampa, FloridaH.Lee Moffitt Cancer center
Jan 3, 2022
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma Trial in United States (PDR001, LAG525)
Completed
- Small Cell Lung Cancer
- +7 more
- PDR001
- LAG525
-
San Francisco, California
- +19 more
May 4, 2022
Stage III NSCLC Trial in Seoul (standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001,
Withdrawn
- Stage III NSCLC
- standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001
- PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
-
Seoul, Korea, Republic ofDepartment of Oncology, Yonsei University College of Medicine
Oct 14, 2020
Gastric Cancer Trial in Seoul (MCS110/PDR001 combination)
Unknown status
- Gastric Cancer
- MCS110/PDR001 combination
-
Seoul, Korea, Republic ofSeoul National University Hospital
Apr 8, 2019